Product Information
ROFLUMILAST 250 MCG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $1.9069 per EA under NDC 67877073093. Its NADAC has been published 51 times since Jul 9, 2025.
Strength
250 ug/1
Manufacturer
Ascend Laboratories, LLCNDC
67877073093
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
ROFLUMILASTApproval Type
Generic (ANDA)
FDA Application
ANDA212490On Market Since
3/14/2025
Pharmacological Classes
Price Statistics
The NADAC for ROFLUMILAST 250 MCG TABLET has been published 51 times since Jul 9, 2025, and over the history we have for it it has declined 16.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9069 per EA |
|---|---|
| All-time high | $2.4855 (Sep 10, 2025) |
| All-time low | $1.9069 (Jun 17, 2026) |
| 52-week high | $2.4855 |
| 52-week low | $1.9069 |
| Median price | $2.2887 |
| Average price | $2.2315 |
| Largest weekly change | -8.5% (Apr 22, 2026) |
| Weeks tracked | 51 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
The matcher finds 4 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 4 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ROFLUMILAST 250 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 250 MCG TABLET, manufactured by Ascend Laboratories, LLC, is $1.9069 per EA (NDC 67877073093), effective Jun 24, 2026.
How has the price of ROFLUMILAST 250 MCG TABLET changed over time?
Over the history we have for it, the NADAC for ROFLUMILAST 250 MCG TABLET has declined 16.0%. It has been tracked across 51 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for ROFLUMILAST 250 MCG TABLET?
Since Jul 9, 2025, the NADAC for ROFLUMILAST 250 MCG TABLET has ranged from a low of $1.9069 (Jun 17, 2026) to a high of $2.4855 (Sep 10, 2025), with a median of $2.2887 per EA.
Are there cheaper alternatives to ROFLUMILAST 250 MCG TABLET?
4 NADAC-published products share the same active ingredient, strength, and dosage form as ROFLUMILAST 250 MCG TABLET, but none are currently priced below it.
Who manufactures ROFLUMILAST 250 MCG TABLET?
ROFLUMILAST 250 MCG TABLET (NDC 67877073093) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification